Barbara Vergani

Conclusions Primary CRC is a human malignancy in which local immunity, estimated by the quantification and spatial distribution of CD8+ T cells, acts as a positive prognostic factor and the best predictor of DFS, more efficiently than the tumor-node-metastasis staging.35 This strong adaptive immune response is believed to reflect the rich T cell neoantigen repertoire expressed by CRC tumors as a consequence of specific genetic profiles (eg, MSI-H/dMMR).36 However, a high Immunoscore is...

3D culture of Erdheim-Chester disease tissues unveils histiocyte metabolism as a new therapeutic target Antonello Villa1, Daniela Belloni2, Barbara Vergani1, Simone Cenci3, Giulio Cavalli4,5, Riccardo Biavasco5,6, Monica Rodolfo7, Maria Giulia Cangi8, Claudio Doglioni5,8, Lorenzo Dagna4,5, Elisabetta Ferrero2, Marina Ferrarini2 1 Consorzio MIA, University of Milano-Bicocca, Milan, Italy 2 Division of Experimental Oncology, San Raffaele Scientific Institute, Milan, Italy 3 Division of Genetics...

Erdheim-Chester disease (ECD) is a rare non-Langerhans cell histiocytosis, characterised by tissue infiltration by foamy CD68+ CD1a− histiocytes.1 The disease has pleomorphic clinical manifestations, including long bones and extraskeletal involvement, and may be life-threatening, particularly when heart and central nervous system are affected.1 ECD histiocytes secrete proinflammatory cytokines2 and carry activating mutations along the RAS-RAF-MEK-ERK protein kinase signalling pathway, most...